Foundation Model-Based Biomarker Platform for Radiology and Clinical Trials

Objectif

The FoundRa project is based on 2 challenges: (1) Due to aging and population growth, there is an increase in pathologies that require radiology, from diagnosis to follow-up. (2) The ambition to make personalized medicine the standard of the future requires all kinds of biomarkers.
Raidium is an agile, young and ambitious French company, born from the mission of the co-founders to accelerate the application of precision medicine and relieve radiologists from their enormous workload.
Raidium delivers the first scalable interactive AI platform for radiology, supporting radiologists in their work, enabling a broader group of clinicians to benefit from radiology insights, and making clinical trials faster and more cost-effective. The innovation is a multimodal foundation model (FM) that uses self-supervised learning based on unlabeled data, creating scalable biomarkers; unlike current offerings where biomarker-generating AI can only target one segment, due to the time- and cost-consuming effort of supervised learning based on manually labeled data. The human-centric platform offers an intelligent interactive and intuitive human-machine interface that can be trained by the radiologist, leveraging their experience while performing automatic segmentation, annotation and analytical tasks, providing reports and decision support.
Radium's beachhead market is to be an AI-enabled contract research organization for pharmaceutical companies, providing strategic AI-generated biomarkers. Radium's ultimate market is to provide an AI radiology platform as a Software as a Service (SaaS) to radiologists and clinical researchers in hospitals and pharma.
With the support from EIC, we will train our FM, integrate it into our platform, and accelerate the creation of AI-based biomarkers. This initiative aims to revolutionize and bring about significant advances in the fields of precision medicine in respect to medical practice and clinical trials.